Article Details
Retrieved on: 2021-02-01 12:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Their addition is intended to minimize delays in enrollment due to the COVID-19 pandemic, AzurRx BioPharma, the treatment's developer, announced.
Article found on: cysticfibrosisnewstoday.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here